Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit
Open Access
- 20 June 2018
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 18 (1) , 197
Abstract
Although neonates and young infants with cholestasis are commonly treated with either phenobarbital or ursodeoxycholic acid (ursodiol), there is no evidence that phenobarbital is effective for this indication. Our objective was to compare the effectiveness of ursodiol and phenobarbital for the treatment of cholestasis in a diverse NICU population. This is a retrospective cohort study including infants with cholestasis who were admitted to a Level IV NICU between January 2010 and December 2015. Drug courses of phenobarbital and ursodiol were identified within the medical record, and medical, demographic, and drug information were extracted. The primary outcome was reduction in direct bilirubin. Sixty-eight infants provided a total of 112 courses of drug therapy for comparison. Diverse medical diagnoses were captured in the patient cohort. Ursodiol was significantly more effective in reducing direct bilirubin than was phenobarbital (− 1.89 vs + 0.76 mg/dL; − 33.33 vs + 13.0 umol/L, p-value 0.03), even after controlling for baseline cholestasis severity, intrauterine growth restriction status, and lipid lowering therapy (− 2.16 vs + 0.27 mg/dl; − 36.94 vs + 4.62 umol/L, p-value 0.03). There was no improvement in direct bilirubin in the majority of infants treated with phenobarbital. Phenobarbital, as compared to ursodiol, has limited efficacy for the reduction of direct bilirubin in neonates and young infants with cholestasis. Given new data regarding the potential neurotoxicity of phenobarbital in the developing brain, providers may choose to avoid phenobarbital in the treatment of cholestasis in infants.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of phenobarbitone and ursodeoxycholic acid in drug-augmented hepatobiliary scintigraphy for excluding the diagnosis of obstructive cholestasis in neonatal cholestasis syndromeNuclear Medicine Communications, 2015
- Brief postnatal exposure to phenobarbital impairs passive avoidance learning and sensorimotor gating in ratsEpilepsy & Behavior, 2014
- Risk Factors for Developing Transient Neonatal CholestasisJournal of Pediatric Gastroenterology and Nutrition, 2012
- Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the ratNeuropharmacology, 2012
- Ursodeoxycholic Acid Treatment in Preterm Infants: A Pilot Study for the Prevention of Cholestasis Associated With Total Parenteral NutritionJournal of Pediatric Gastroenterology and Nutrition, 2008
- Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants.2006
- Antiepileptic drugs and apoptotic neurodegeneration in the developing brainProceedings of the National Academy of Sciences, 2002
- Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisitedHepatology, 2002
- Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver diseaseThe Journal of Pediatrics, 2002
- Phenobarbital Effects in Cholestatic Liver DiseaseAnnals of Internal Medicine, 1975